Results 41 to 50 of about 52,343 (282)

The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines

BMC Cancer, 2019
Background High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 has become a treatment approach ...
Stefanie Klenke, Neval Akdeli, Patrick Stelmach, Lukas Heukamp, Johannes H. Schulte, Hagen S. Bachmann   +5 more
doaj   +1 more source

Pharmacogenetics of asthma [PDF]

American Journal of Respiratory and Critical Care Medicine, 2002
Anthony G. Fenech, Ian P. Hall
openalex   +3 more sources

miRNAs as Key Players in the Management of Cutaneous Melanoma

Cells, 2020
The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso, Simona De Summa, Rosamaria Pinto, Katia Danza, Stefania Tommasi   +4 more
doaj   +1 more source

Pharmacogenetics in Psychiatry: An Update on Clinical Usability

Frontiers in Pharmacology, 2020
Using pharmacogenetics in guiding drug therapy experiences a steady increase in uptake, although still leads to discussions as to its clinical use. Psychiatry constitutes a field where pharmacogenomic testing might help in guiding drug therapy.
R. V. van Schaik, D. Müller, A. Serretti, M. Ingelman-Sundberg   +3 more
semanticscholar   +1 more source

Pharmacogenetics of Cannabinoids [PDF]

European Journal of Drug Metabolism and Pharmacokinetics, 2017
Although the application of medical marijuana and cannabinoid drugs is controversial, it is a part of modern-day medicine. The list of diseases in which cannabinoids are promoted as a treatment is constantly expanding. Cases of significant improvement in patients with a very poor prognosis of glioma or epilepsy have already been described. However, the
Oliwia Zakerska-Banaszak, Michal Walczak, Marzena Skrzypczak-Zielinska, Szymon Hryhorowicz, Ryszard Słomski   +4 more
openaire   +3 more sources

Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma

Hepatology Communications, 2022
The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism.
Yang Xie, Runzi Sun, Li Gao, Jibin Guan, Jingyuan Wang, Aaron Bell, Junjie Zhu, Min Zhang, Meishu Xu, Peipei Lu, Xinran Cai, Songrong Ren, Pengfei Xu, Satdarshan P. Monga, Xiaochao Ma, Da Yang, Yulan Liu, Binfeng Lu, Wen Xie   +18 more
doaj   +1 more source

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Clinical Pharmacokinetics, 2018
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer.
F. D. de Man, A. Goey, R. V. van Schaik, R. Mathijssen, S. Bins   +4 more
semanticscholar   +1 more source

Exonic Variation and Its Clinical Impact in 7221 Old Order Amish

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The Amish of Lancaster County, PA has been the focus of genetic studies for many years due to its demographic history and unique genetic makeup that includes a historical bottleneck event and subsequent genetic drift, resulting in a marked decrease in genetic diversity and increased frequency of some variants that have substantially shaped the
Braxton D. Mitchell, Ebuka Onyenobi, Joshua P. Lewis, Brady Gaynor, James A. Perry, Kristin Maloney, Jeffrey R. O'Connell, Jessica Tiner, Amber L. Beitelshees, Cristopher V. Van Hout, Patrick F. McArdle, Huichun Xu, Erik G. Puffenberger, Karlla W. Brigatti, Melanie Daue, Hilary B. Whitlatch, Anna Alkelai, Alejandro A. Schäffer, John Overton, Elizabeth A. Streeten, Toni I. Pollin, Alan R. Shuldiner   +21 more
wiley   +1 more source

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

BMC Medicine, 2019
Background Pharmacogenetics (PGx) is currently implemented in hospitals to optimize therapy with high-risk drugs. However, many drugs with dosing recommendations from the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics ...
P. C. D. Bank, J. J. Swen, H. J. Guchelaar   +2 more
doaj   +1 more source

Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective

Frontiers in Genetics, 2020
Introduction Aberrant pharmacogenetic variants occur in a high proportion of people and might be relevant for the prescription of over 26 drugs in primary care.
T. Rigter, M. Jansen, Jordy M. de Groot, S. Janssen, W. Rodenburg, M. Cornel   +5 more
semanticscholar   +1 more source